205 related articles for article (PubMed ID: 22675174)
1. Molecular profiling reveals low- and high-grade forms of primary melanoma.
Harbst K; Staaf J; Lauss M; Karlsson A; Måsbäck A; Johansson I; Bendahl PO; Vallon-Christersson J; Törngren T; Ekedahl H; Geisler J; Höglund M; Ringnér M; Lundgren L; Jirström K; Olsson H; Ingvar C; Borg Å; Tsao H; Jönsson G
Clin Cancer Res; 2012 Aug; 18(15):4026-36. PubMed ID: 22675174
[TBL] [Abstract][Full Text] [Related]
2. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
3. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.
Nsengimana J; Laye J; Filia A; Walker C; Jewell R; Van den Oord JJ; Wolter P; Patel P; Sucker A; Schadendorf D; Jönsson GB; Bishop DT; Newton-Bishop J
Oncotarget; 2015 May; 6(13):11683-93. PubMed ID: 25871393
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
5. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
[TBL] [Abstract][Full Text] [Related]
6. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
[TBL] [Abstract][Full Text] [Related]
7. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM; Jackson GL; Greisinger AJ; Maetzold D; Delman KA; Lawson DH; Stone JF
Clin Cancer Res; 2015 Jan; 21(1):175-83. PubMed ID: 25564571
[TBL] [Abstract][Full Text] [Related]
8. Evolutionary Routes in Metastatic Uveal Melanomas Depend on
Rodrigues M; Mobuchon L; Houy A; Alsafadi S; Baulande S; Mariani O; Marande B; Ait Rais K; Van der Kooij MK; Kapiteijn E; Gassama S; Gardrat S; Barnhill RL; Servois V; Dendale R; Putterman M; Tick S; Piperno-Neumann S; Cassoux N; Pierron G; Waterfall JJ; Roman-Roman S; Mariani P; Stern MH
Clin Cancer Res; 2019 Sep; 25(18):5513-5524. PubMed ID: 31227496
[TBL] [Abstract][Full Text] [Related]
9. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome.
Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE
Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death.
Onken MD; Worley LA; Ehlers JP; Harbour JW
Cancer Res; 2004 Oct; 64(20):7205-9. PubMed ID: 15492234
[TBL] [Abstract][Full Text] [Related]
12. Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis.
Donizy P; Kaczorowski M; Leskiewicz M; Zietek M; Pieniazek M; Kozyra C; Halon A; Matkowski R
Oncol Rep; 2014 Dec; 32(6):2735-43. PubMed ID: 25310673
[TBL] [Abstract][Full Text] [Related]
13. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
[TBL] [Abstract][Full Text] [Related]
14. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
15. De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.
Cymerman RM; Shao Y; Wang K; Zhang Y; Murzaku EC; Penn LA; Osman I; Polsky D
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27235387
[TBL] [Abstract][Full Text] [Related]
16. A time course-dependent metastatic gene expression signature predicts outcome in human metastatic melanomas.
Chen R; Zhang G; Zhou Y; Li N; Lin J
Diagn Pathol; 2014 Aug; 9():155. PubMed ID: 25116415
[TBL] [Abstract][Full Text] [Related]
17. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
Madore J; Strbenac D; Vilain R; Menzies AM; Yang JY; Thompson JF; Long GV; Mann GJ; Scolyer RA; Wilmott JS
Clin Cancer Res; 2016 Aug; 22(15):3915-23. PubMed ID: 26960397
[TBL] [Abstract][Full Text] [Related]
19. Expression of microRNA-106b and its clinical significance in cutaneous melanoma.
Lin N; Zhou Y; Lian X; Tu Y
Genet Mol Res; 2015 Dec; 14(4):16379-85. PubMed ID: 26662433
[TBL] [Abstract][Full Text] [Related]
20. MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas.
Valentini V; Zelli V; Gaggiano E; Silvestri V; Rizzolo P; Bucalo A; Calvieri S; Grassi S; Frascione P; Donati P; Soda G; Ottini L; Richetta AG
Anticancer Res; 2019 Aug; 39(8):4085-4093. PubMed ID: 31366492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
